News Release

University of Oklahoma researchers contribute to federal initiative tackling antibiotic resistance

Grant and Award Announcement

University of Oklahoma

Zgurskya and Rybenkov


University of Oklahoma faculty Helen I. Zgurskaya and Valentin V. Rybenkov are contributing their expertise in drug efflux and permeation mechanisms to a $104 million federal initiative to study antibiotic resistance.

view more 

Credit: Photo provided by the University of Oklahoma

University of Oklahoma faculty Helen I. Zgurskaya and Valentin V. Rybenkov are contributing to a $104 million federal initiative to study antibiotic resistance. Harvard Medical School professor Johan Paulsson leads the multi-institutional research team.

The initiative, “DARTS: Defeating Antibiotic Resistance through Transformative Solutions,” is funded by the Advanced Research Projects Agency for Health, or ARPA-H, of the U.S. Department of Health and Human Services. The project aims to address the critical healthcare challenge of increasingly resilient bacteria by “advancing an ultra-high throughput imaging and culturing platform that can continuously track and test billions of bacteria one by one.”

As one of twenty-five collaborating groups from industry, academy and clinics working on the project, the OU team will contribute their expertise in drug efflux and permeation mechanisms.

“The project is focused on how antibiotic resistance arises and on the characterization of rare cells that survive during antibiotic treatments in clinics,” Zgurskaya said. “These survivors are in a different state than rapidly growing cells. We will characterize how drugs get inside these cells, how drug efflux works in these survivors and what kind of antibiotics are more likely to trigger the appearance of survivors.”

“What makes this novel is not that 25 research groups are funded to study antibiotic resistance, but that 25 groups with expertise in optics, mathematics, microbiology, and medicine can come together and do that as one coordinated team,” said Paulsson in a press release.

This project will also enable valuable opportunities for students working in Rybenkov and Zgurskaya’s labs. Students will gain experience using a technology that isolates and analyzes single bacterial cells developed at Harvard, as well as drug efflux and permeation quantification technology developed at OU and machine learning applications in drug efflux and permeation also developed by Rybenkov and Zgurskaya’s labs.

Learn more about the APRA-H funding initiative, the DART project, or Rybenkov and Zgurskata’s research via the Center for Antibiotic Discovery and Resistance.


About the University of Oklahoma

Founded in 1890, the University of Oklahoma is a public research university in Norman, Oklahoma. As the state’s flagship university, OU serves the educational, cultural, economic and health care needs of the state, region and nation. OU was named the state’s highest-ranking university in U.S. News & World Report’s most recent Best Colleges list. For more information about the university, visit

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.